SH3TC2 and cancer: SH3TC2 was found to be dysregulated in 9 cancers, including BLCA, CHOL, COAD, LAML, PAAD, READ, SKCM, BRCA, and TGCT, and correlated with patient DFS in 4 cancers, including COAD, MESO, PAAD, and READ.